AzurRx BioPharma to Participate in the 33rd Annual Roth Conference
March 08 2021 - 7:00AM
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX),
a company specializing in the development of targeted non-systemic,
recombinant therapies for gastrointestinal (GI) diseases,
today announced that James Sapirstein, Chairman and Chief Executive
Officer, will participate in a panel discussion during the 33rd
Annual Roth Conference being held virtually from March 15-17, 2021.
The panel, entitled “Therapeutics Against SARS-CoV-2 – Viral
Variants Will Not Fade Away: A discussion of various
developmental therapeutics for SARS-CoV-2 infection,” is scheduled
for March 15, 2021 from 12:00 to 1:00 p.m., ET. During the panel,
Mr. Sapirstein will discuss the need for drug therapies to address
issues related to COVID-19, including the prevalence of
gastrointestinal symptoms in an increasing number of people who
have been infected by the virus. AzurRx is currently advancing
FW-1022 (micronized niclosamide) for the potential treatment of
COVID-19 gastrointestinal infections.
Additionally, during the conference Mr. Sapirstein and members
of the AzurRx management team will be participating in virtual
one-on-one meetings with registered investors and pharmaceutical
companies.
Details of the panel discussion are as follows:
Event: |
|
33rd Annual Roth Conference |
Panel: |
|
Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade
Away: A discussion of various developmental therapeutics for
SARS-CoV-2 infection |
Date: |
|
March 15, 2021 |
Time: |
|
12:00 – 1:00 p.m., ET |
Registration: |
|
https://www.meetmax.com/sched/event_70981/conference_register.html |
About AzurRx BioPharma, Inc.AzurRx BioPharma,
Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases. The Company has a pipeline of
three gut-restricted GI clinical programs. The lead therapeutic
candidate is MS1819, a recombinant lipase for the treatment of
exocrine pancreatic insufficiency (EPI) in patients with cystic
fibrosis and chronic pancreatitis, currently in two Phase 2
clinical trials. AzurRx is launching two clinical programs using
proprietary formulations of niclosamide, a pro-inflammatory pathway
inhibitor; FW-420, for grade 1 Immune Checkpoint
Inhibitor-Associated Colitis and diarrhea in oncology patients
and FW-1022, for COVID-19 gastrointestinal infections. The
Company is headquartered in Delray Beach, Florida. with clinical
operations in Hayward, California. For more information
visit www.azurrx.com.
Forward-Looking StatementsThis press release
may contain certain statements relating to future results which are
forward-looking statements. These statements are not historical
facts, but instead, represent only the Company’s belief regarding
future events, many of which, by their nature, are inherently
uncertain and outside of the Company’s control. It is possible that
the Company’s actual results and financial condition may differ,
possibly materially, from the anticipated results and financial
condition indicated in these forward-looking statements, depending
on factors including whether results obtained in preclinical and
nonclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; whether preliminary or
interim results from a clinical trial such as the interim results
presented will be indicative of the final results of the trial; and
the Company’s success in raising additional financing to support
its operations. Additional information concerning the Company and
its business, including a discussion of factors that could
materially affect the Company’s financial results, including those
related to the clinical development of MS1819, the results of its
clinical trials, and the impact of the coronavirus (COVID-19)
pandemic on the Company’s operations and current and planned
clinical trials, including, but not limited to delays in clinical
trial recruitment and participation are contained in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2019
under the heading “Risk Factors,” as well as the
Company’s subsequent filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.
For more information:
AzurRx BioPharma, Inc.1615 South Congress AvenueSuite 103Delray
Beach, Florida 33445Phone: (646) 699-7855info@azurrx.com
Media contact:
Tiberend Strategic Advisors, Inc.Johanna Bennett/Ingrid
Mezo(212) 375-2665/(646)
604-5150jbennett@tiberend.com/imezo@tiberend.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2023 to Apr 2024